RegCell, Inc., a biotechnology company focused on restoring immune tolerance, announced on September 15, 2026 that it has secured $66 million in additional funding. The total combines a fully subscribed $44 million Series A financing led by Playground Global and a second non-dilutive grant from Japan’s Agency for Medical Research and Development, or AMED. The capital will advance RegCell’s epigenetic reprogramming platform into clinical-stage development for multiple autoimmune indications.
Financial Backing and Investor Support
The $44 million Series A was joined by new investors including Global Brain, Mitsui Chemicals, LG Technology Ventures, Alumni Ventures, and Medical Incubator Japan. Existing investors such as Fast Track Initiative, UTEC, Osaka University Venture Capital, and Kyoto iCAP also participated. Jory Bell, General Partner at Playground Global, will join RegCell’s Board of Directors as part of the financing.
The AMED award adds approximately $22 million, or ¥3.4 billion, in non-dilutive funding to the company’s resources. This is RegCell’s second AMED grant and raises the agency’s total commitment to roughly $59.3 million, or ¥9.0 billion. The first award in 2024 provided about $37.3 million to develop the initial generation of the platform through clinical proof-of-concept in autoimmune liver diseases.
Science and Platform Differentiation
RegCell’s approach is built on Nobel Laureate and co-founder Professor Shimon Sakaguchi’s discovery of regulatory T cells, or Tregs. The platform converts disease-causing T cells into stable, epigenetically reprogrammed, antigen-specific Tregs that restore immune tolerance at its source. Unlike conventional immunosuppressants, this strategy is designed to distinguish harmful immune cells from healthy ones and avoid broadly dampening immune function.
Because RegCell’s method requires no gene engineering, it offers simplified manufacturing, enhanced safety, and greater scalability across patient populations. The company says it targets unknown or multiple pathogenic antigens to overcome limitations of existing therapies that block cytokines, impede cell trafficking, or deplete immune cells. This upstream mechanism may provide durable restoration of tolerance while preserving normal immune activity.
Clinical Development Objectives
The combined financing will enable an investigational new drug submission and support the advancement of RegCell’s next-generation platform into a second autoimmune indication through Phase 2 as proof of concept. The new AMED grant will also accelerate development of lineage-stable antigen-specific Tregs and expand the clinical pipeline. RegCell’s President and CEO Michael V. McCullar said the company intends to rapidly advance the platform and establish proof of concept in patients.
Executive and Investor Outlook
Playground Global General Partner Jory Bell stated that RegCell is pursuing a genuinely novel approach by reprogramming a patient’s own auto-reactive T cells to reset the immune system. He noted the potential to move beyond symptom management toward something closer to a cure for conditions such as myasthenia gravis, rheumatoid arthritis, and ulcerative colitis. Investors from Fast Track Initiative and UTEC also expressed confidence in the company’s ability to change how autoimmune disease is treated.
RegCell’s $66 million funding milestone reflects strong government and investor confidence in its Nobel Prize-winning scientific foundation. The company’s epigenetic reprogramming platform offers a potentially durable alternative to broad immunosuppression by restoring immune tolerance at the source. With clinical-stage development now in view, RegCell is positioned to test whether this approach can deliver meaningful benefits across multiple autoimmune diseases.